Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced it has entered into a manufacturing services agreement with a U.S. manufacturer for clinical supply of its lead compound PH-762. The agreement covers both clinical and commercial supply manufacturing for future clinical trials.

The clinical-stage biopharmaceutical company develops therapeutics using its INTASYL gene silencing technology. PH-762 is being evaluated as an intratumoral therapy for cutaneous carcinomas in a Phase 1b trial.

"It is a pleasure to partner with an organization known for its quality and expertise in drug product manufacturing services," said Robert Bitterman, Phio's President and CEO. "Further, we value the strategic advantages of working with a U.S. based organization."

In the Phase 1b trial, 22 patients completed treatment across five dose-escalation cohorts with no dose-limiting toxicities or serious adverse events reported. The company reported a pathological response rate in cutaneous squamous cell carcinoma of approximately 65% across all dosing cohorts, including an 85% pathological response rate in six of seven patients in the highest-dose cohort.

Phio indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026. The company reported cash and cash equivalents projected to sustain operations into the first half of 2027.